Herceptin Research Today is a free monthly online journal that collates and summarizes the latest research about Herceptin, including details on side-effects, breast cancer, treatment, therapy.

Volume 5 (2008), Issue 1 (January)

1. Her-2/neu expression in salivary duct carcinoma: an immunohistochemical and chromogenic in situ hybridization study.
   Appl Immunohistochem Mol Morphol, 16(1): 54-8. [Abstract] [Full-text]
2. Cardiac toxicity in breast cancer survivors: review of potential cardiac problems.
   Clin Cancer Res, 14(1): 14-24. [Abstract] [Full-text]
3. Cytogenetic analysis of HER1/EGFR, HER2, HER3, AND HER4 in 278 breast cancer patients.
   Breast Cancer Res, 10(1): R2. [Abstract] [Full-text]
4. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses.
   Breast Cancer Res Treat. [Abstract] [Full-text]
5. HER-2/neu overexpression and amplification in uterine serous papillary carcinoma: comparative analysis of immunohistochemistry, real-time reverse transcription-polymerase chain reaction, and fluorescence in situ hybridization.
   Int J Gynecol Cancer, 18(1): 14-21. [Abstract] [Full-text]
6. CD40 signaling predicts response to preoperative trastuzumab and concomitant paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide in HER-2-overexpressing breast cancer.
   Breast Cancer Res, 9(6): R87. [Abstract] [Full-text]
7. Quantitative aspects of the analysis of the monoclonal antibody trastuzumab using high-performance liquid chromatography coupled with electrospray mass spectrometry.
   J Pharm Biomed Anal, 46(3): 449-55. [Abstract] [Full-text]
8. HER2 Targeted Polyplexes: The Effect of Polyplex Composition and Conjugation Chemistry on in Vitro and in Vivo Characteristics.
   Bioconjug Chem, 19(1): 244-53. [Abstract] [Full-text]
9. Cell studies of a three-component antisense MORF/tat/Herceptin nanoparticle designed for improved tumor delivery.
   Cancer Gene Ther, 15(2): 126-32. [Abstract] [Full-text]
10. HER2 in well differentiated breast cancer: is testing necessary?
    Breast Cancer Res Treat. [Abstract] [Full-text]
11. Trastuzumab signaling in ErbB2-overexpressing inflammatory breast cancer correlates with X-linked inhibitor of apoptosis protein expression.
    Mol Cancer Ther, 7(1): 38-47. [Abstract] [Full-text]
12. Trastuzumab decreases the number of circulating and disseminated tumor cells despite trastuzumab resistance of the primary tumor.
    Cancer Lett, 260(1): 198-208. [Abstract] [Full-text]
13. HER2+ breast cancer: review of biologic relevance and optimal use of diagnostic tools.
    Am J Clin Pathol, 129(2): 263-73. [Abstract] [Full-text]
14. Revoking the privilege: targeting HER2 in the central nervous system.
    Mol Pharmacol, 73(2): 271-3. [Abstract] [Full-text]
15. Cellular and in vivo activity of JNJ-28871063, a nonquinazoline pan-ErbB kinase inhibitor that crosses the blood-brain barrier and displays efficacy against intracranial tumors.
    Mol Pharmacol, 73(2): 338-48. [Abstract] [Full-text]
16. Vascular endothelial growth factor partially inhibits the trastuzumab-mediated antibody-dependent cellular cytotoxicity of human monocytes.
    Oncology, 72(3): 172-80. [Abstract] [Full-text]
17. Trastuzumab monotherapy versus combination therapy for treating recurrent breast cancer: time to progression and survival.
    Breast Cancer, 15(1): 57-64. [Abstract] [Full-text]
18. Considerations in treatment choice for metastatic breast cancer.
    Breast Cancer, 15(1): 35-9. [Abstract] [Full-text]
19. Heterogeneity of breast cancer and implications of adjuvant chemotherapy.
    Breast Cancer, 15(1): 31-4. [Abstract] [Full-text]
20. Direct 99m Tc labeling of Herceptin (trastuzumab) by 99m Tc(I) tricarbonyl ion.
    Appl Radiat Isot, 66(3): 340-5. [Abstract] [Full-text]
21. Epitope mapping and structural analysis of an anti-ErbB2 antibody A21: Molecular basis for tumor inhibitory mechanism.
    Proteins, 70(3): 938-49. [Abstract] [Full-text]
22. Common adjuvant breast cancer therapies do not inhibit cancer vaccine induced T cell immunity.
    Breast Cancer Res Treat. [Abstract] [Full-text]

© 2004-2008 Herceptin Research Today. All Rights Reserved.